Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CLASSYS Inc. (214150.KQ)
Seoul, KR
CLASSYS Inc. is a global supplier of sophisticated medical aesthetic devices. Its diverse product range features SCIZER, a non-invasive solution for subcutaneous fat reduction; ULTRAFORMER MPT, which employs focused ultrasound stimulation for skin tissue coagulation to achieve eyebrow lifts; and ULTRAFORMER III, a high-intensity focused ultrasound (HIFU) surgical device designed for tissue coagulation, aiding in eyelid lifting, skin tightening, and improving subcutaneous tissue elasticity across the face (cheeks), abdomen, and thighs, while also diminishing crow's feet, laugh lines, and neck wrinkles. Additional offerings include INTRASURE, a versatile multi-platform solution for aesthetics and healthcare; FORSHAPE, an RF treatment system engineered to boost metabolism, enhance blood circulation, and facilitate tissue recovery; and VOLNEWMER, a monopolar radiofrequency therapeutic equipment used for skin tissue coagulation as a general electrosurgical instrument. The company's portfolio further encompasses CLATUU Alpha, a medical device that progressively reduces subcutaneous fat layers, particularly in areas of excessive accumulation, using low-temperature energy and negative pressure; Ulfit, which utilizes HIFU energy to improve skin elasticity and subcutaneous tissue in the abdomen and thighs; Refit, a medical device combining RF and negative pressure to elevate tissue temperature and blood flow, thereby alleviating pain in treated areas; AQUAPURE, equipped with four distinct handpieces for applications such as acne suction and various forms of pain relief, including muscle pain; and AQUAPURE II, a multi-functional device for comprehensive facial and body care. These products are marketed under the Classys, Cluederm, and SKEDERM brands. CLASSYS serves a broad client base, including clinics, hospitals, and beauty salons. The company was founded in 2007 and is headquartered in Seoul, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.26% | -6.20% | -18.13% | -32.32% | -12.25% | -18.69% | -20.58% | +80.83% | +232.06% | +932.50% | +932.50% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 8 | 0 |
| Buy | 8 | -1 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+38.6% ★ Q1'26: +13.0% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+33.4% ★ Q1'26: +12.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+33.2% ★ Q1'26: +9.2% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+50.7% ★ Q1'26: +42.7% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+38.4% ★ Q1'26: +22.5% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+2.1% Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.35× ★ Q1'26: 0.87× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 18 Rev. Ana. 15 EPS Ana. |
Dec 2027 18 Rev. Ana. 18 EPS Ana. |
Dec 2028 8 Rev. Ana. 9 EPS Ana. |
Dec 2029 11 Rev. Ana. 10 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
180.12B
est: 184.06B (-2.1%)
|
242.94B
est: 239.62B (+1.4%)
|
336.80B
est: 341.18B (-1.3%)
|
467.17B
433.58B – 493.69B
+36.9% YoY
|
581.44B
516.99B – 638.35B
+24.5% YoY
|
681.82B
618.09B – 736.07B
+17.3% YoY
|
788.00B
714.34B – 850.69B
+15.6% YoY
|
| EBITDA |
93.90B
est: 99.27B (-5.4%)
|
137.19B
est: 128.83B (+6.5%)
|
185.20B
est: 183.44B (+1.0%)
|
251.17B
233.12B – 265.43B
+36.9% YoY
|
312.61B
277.96B – 343.21B
+24.5% YoY
|
366.58B
332.32B – 395.75B
+17.3% YoY
|
423.67B
384.06B – 457.38B
+15.6% YoY
|
| EBIT |
89.62B
est: 94.37B (-5.0%)
|
129.97B
est: 121.67B (+6.8%)
|
170.60B
est: 173.24B (-1.5%)
|
237.21B
220.16B – 250.68B
+36.9% YoY
|
295.24B
262.51B – 324.14B
+24.5% YoY
|
346.21B
313.85B – 373.76B
+17.3% YoY
|
400.13B
362.72B – 431.96B
+15.6% YoY
|
| Net Income |
74.23B
est: 77.43B (-4.1%)
|
97.88B
est: 98.05B (-0.2%)
|
131.90B
est: 129.67B (+1.7%)
|
178.32B
170.22B – 193.14B
+37.5% YoY
|
227.89B
183.49B – 268.79B
+27.8% YoY
|
267.64B
235.11B – 295.32B
+17.4% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
38.73B
est: 24.51B (+58.0%)
|
32.91B
est: 36.89B (-10.8%)
|
62.17B
est: 52.52B (+18.4%)
|
71.91B
66.74B – 76.00B
+36.9% YoY
|
89.51B
79.58B – 98.27B
+24.5% YoY
|
104.96B
95.15B – 113.31B
+17.3% YoY
|
121.30B
109.96B – 130.95B
+15.6% YoY
|
| EPS |
1,155.00
est: 1,206.89 (-4.3%)
|
1,517.00
est: 1,496.83 (+1.3%)
|
2,013.57
est: 1,979.51 (+1.7%)
|
2,722.23
2,598.59 – 2,948.44
+37.5% YoY
|
3,478.90
2,801.17 – 4,103.28
+27.8% YoY
|
4,085.71
3,589.19 – 4,508.28
+17.4% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive team data is not available for this company yet.
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 214150.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
